<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000126</url>
  </required_header>
  <id_info>
    <org_study_id>UWarmiaMazury</org_study_id>
    <nct_id>NCT04000126</nct_id>
  </id_info>
  <brief_title>Pupillometry - Future of Objective Pain Reaction Measurement While Unconscious</brief_title>
  <official_title>Pupillometry - Future of Objective Pain Reaction Measurement While Unconscious</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warmia and Mazury</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Warmia and Mazury</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the usefulness of pupillometry as a nociceptive indicator during&#xD;
      elective orotracheal intubation in patients given intravenous lignocaine pre-intubation as&#xD;
      compared to a placebo pre-intubation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laryngoscopy and tracheal intubation are associated with a sympathetic discharge caused by&#xD;
      stimulation of the upper respiratory tract. Venous lidocaine is the agent most used to&#xD;
      attenuate the hemodynamic response to laryngoscopy and intubation. Hemodynamic response might&#xD;
      be masked by the drugs the patient is taking and its status (ex. sepsis). There's a need for&#xD;
      an objective pain assessment method while the patient is unconscious, to maintain a proper&#xD;
      level of analgesia and to control the hemodynamic response in order to decrease systemic&#xD;
      repercussions.&#xD;
&#xD;
      This single-blind, randomized, single center, prospective study was approved by the Bioethics&#xD;
      Committee of the University of Warmia and Mazury under the report number 11/2019 21st of&#xD;
      February 2019.&#xD;
&#xD;
      Patients scheduled for elective surgery under general anesthesia with tracheal intubation&#xD;
      were divided into three groups:&#xD;
&#xD;
      Group 1: anaesthetic induction with standard doses iv was performed (fentanyl 3mcg/kg,&#xD;
      propofol 2mg/kg, rocuronium 0,6mg/kg).&#xD;
&#xD;
      Group 2: same as in group 1 + lidocaine 1,5mg/kg w 100ml 0,9% NaCl 10 min before intubation.&#xD;
&#xD;
      Group 3 (placebo group): same as group 1 + 100ml 0,9% NaCl 10 min before intubation&#xD;
&#xD;
      The values for blood pressure (NIBP), heart rate (HR), Train of four (TOF) and bispectral&#xD;
      index (BIS) were measured in all groups during the whole time of the protocol. PRD (Pupillary&#xD;
      Reflex Dilation) was measured in the exact time of intubation. Additionally, after intubation&#xD;
      PPI (Pupillary Pain Index) was checked.&#xD;
&#xD;
      During the whole protocol BIS value was maintained to be equal to or less than 50, if this&#xD;
      value was not reached, a venous increment of 1mg/kg of propofol was administered.&#xD;
&#xD;
      Hypertension was considered when the BP values were 20% above baseline values or if Systolic&#xD;
      Blood Pressure (SBP) &gt; 140 mmHg. Hypotension was considered when the Blood Pressure (BP)&#xD;
      values were 20% below baseline values or if SBP &gt; 90 mmHg. Tachycardia was considered when&#xD;
      the Heart Rate (HR) values were 20% above baseline values or if HR &gt; 100 mmHg. Bradycardia&#xD;
      was considered for HR values under 50 bpm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usefulness of Pupillary Reflex Dilation (PRD) measured using a video pupillometer in determining the role of lidocaine iv before intubation.</measure>
    <time_frame>PRD: during the exact time of intubation (continuous measurement for 60 seconds)</time_frame>
    <description>Level of analgesia will be investigated in all groups (placebo, lidocaine, control) basing on the autonomous system activation during intubation by measuring variation of pupil diameter (% and mm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The influence of intravenous lidocaine on level of analgesia during orotracheal intubation</measure>
    <time_frame>PRD: during the exact time of intubation (continuous measurement for 60 seconds)</time_frame>
    <description>Changes that occur in PRD measured using video pupillometer as a response to an analgesic intervention will be investigated in all groups (placebo, lidocaine, control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The influence of intravenous lidocaine on level of analgesia during orotracheal intubation.</measure>
    <time_frame>HR - baseline and 0,1,2,3,4 minutes post-intubation</time_frame>
    <description>Level of analgesia will be investigated in all groups (placebo, lidocaine, control) basing on the autonomous system activation during intubation by measuring changes in HR (beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The influence of intravenous lidocaine on level of analgesia during orotracheal intubation.</measure>
    <time_frame>BP - baseline and 0,1,2,3,4 minutes post-intubation</time_frame>
    <description>Level of analgesia will be investigated in all groups (placebo, lidocaine, control) basing on the autonomous system activation during intubation by measuring changes in BP (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between PRD and PPI (Pupillary Pain Index) measured using video pupillometer and BIS (Bispectral Index)</measure>
    <time_frame>BIS - baseline, during intubation, 0,1,2,3,4,5 minutes post-intubation, PRD: during the exact time of intubation (continuous measurement for 60 seconds), PPI - 5 minutes post-intubation</time_frame>
    <description>Changes that occur in PRD and PPI as a response to an analgesic intervention will be investigated in all groups (placebo, lidocaine, control) and correlated to BIS in all groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The influence of intravenous lidocaine on PPI</measure>
    <time_frame>5 minutes post-intubation</time_frame>
    <description>Changes that occur in PPI measure using video pupillometer as a response to an analgesic intervention will be investigated in all groups (placebo, lidocaine, control).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be given induction anesthesia agents in standard doses (fentanyl 3mcg/kg, propofol 2mg/ kg, rocuronium 0,6mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given additionally 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be given additionally 100 ml 0,9% NaCl iv 10 min before intubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pupil reflex dilation measurement (PRD)</intervention_name>
    <description>Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer</description>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_label>Placebo P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PPI (Pupillary Pain Index)</intervention_name>
    <description>Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation</description>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_label>Placebo P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation</description>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <other_name>lidocaine, Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100ml 0,9% NaCl iv 10min before intubation</description>
    <arm_group_label>Placebo P</arm_group_label>
    <other_name>0,9% natrium chloratum, sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bispectral Index (BIS)</intervention_name>
    <description>Bispectral Index will be monitored to assess the depth of anaesthesia</description>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_label>Placebo P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HR</intervention_name>
    <description>HR in beats/min will be measured by the electrocardiogram monitor</description>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_label>Placebo P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BP</intervention_name>
    <description>BP will be measured automatically by an occluding upper arm cuff</description>
    <arm_group_label>Control C</arm_group_label>
    <arm_group_label>Lignocaine group L</arm_group_label>
    <arm_group_label>Placebo P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physical State 1 or 2 of the American Society of Anesthesiology (ASA)&#xD;
&#xD;
          -  Electively scheduled for surgery requiring general anesthesia&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Difficult airway&#xD;
&#xD;
          -  Unanticipated difficult airway based on the previous history of difficult intubation&#xD;
&#xD;
          -  Urgently scheduled for surgery requiring general anesthesia&#xD;
&#xD;
          -  Ophthalmologic pathology precluding pupillometry, ex. Horner's syndrome, Sjogrens&#xD;
             syndrome&#xD;
&#xD;
          -  Anisocoria&#xD;
&#xD;
          -  History of opioid abuse&#xD;
&#xD;
          -  Subjects who are or may be pregnant&#xD;
&#xD;
          -  Unable to converse in Polish&#xD;
&#xD;
          -  History of psychiatric/cognitive disease&#xD;
&#xD;
          -  Patients who do not give informed consent&#xD;
&#xD;
          -  Patients with contraindications or history of hypersensitivity to lidocaine&#xD;
&#xD;
          -  Patients with coronary ischemic disease&#xD;
&#xD;
          -  Patients with atrioventricular block at any grade&#xD;
&#xD;
          -  Patients with diagnosed cardiac arrhythmias&#xD;
&#xD;
          -  Patients with heart failure&#xD;
&#xD;
          -  Patients who are taking drugs influencing the pupil size&#xD;
&#xD;
          -  Patients with pacemaker&#xD;
&#xD;
          -  Patients younger than 18 years of age&#xD;
&#xD;
          -  History of chronic pain, chronic opioid use (&gt; 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa Mayzner-Zawadzka, MD,PhD,Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Anesthesiology and Intensive Care Clinical Ward, University of Warmia and Mazury</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anesthesiology and Intensive Care Clinical Ward, Clinical University Hospital</name>
      <address>
        <city>Olsztyn</city>
        <state>Warmian-masurian</state>
        <zip>11-041</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warmia and Mazury</investigator_affiliation>
    <investigator_full_name>Malgorzata Braczkowska</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>intubation</keyword>
  <keyword>pupillometry</keyword>
  <keyword>hemodynamic response</keyword>
  <keyword>pain</keyword>
  <keyword>reflex</keyword>
  <keyword>pupillary monitoring</keyword>
  <keyword>intraoperative</keyword>
  <keyword>analgesia</keyword>
  <keyword>general anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified study participants data for all primary and secondary outcome measures.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data will be made available for researchers who provide a methodologically sound proposal. Proposals should be directed to m.braczkowska@gmail.com . Data access requests will be reviewed by an External Independent Review Panel. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

